| __timestamp | Pfizer Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14097000000 | 7751000 |
| Thursday, January 1, 2015 | 14809000000 | 10251000 |
| Friday, January 1, 2016 | 14837000000 | 9575000 |
| Sunday, January 1, 2017 | 14784000000 | 10912000 |
| Monday, January 1, 2018 | 14455000000 | 11049000 |
| Tuesday, January 1, 2019 | 14350000000 | 11646000 |
| Wednesday, January 1, 2020 | 11615000000 | 13265000 |
| Friday, January 1, 2021 | 12703000000 | 25805000 |
| Saturday, January 1, 2022 | 13677000000 | 35182000 |
| Sunday, January 1, 2023 | 14771000000 | 94999000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Pfizer Inc., a global pharmaceutical giant, and Viridian Therapeutics, Inc., a smaller biotech firm, offer a fascinating contrast in SG&A cost management from 2014 to 2023.
Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This consistency reflects Pfizer's robust operational strategies and scale efficiencies. In contrast, Viridian's SG&A expenses, though significantly lower, have shown a dramatic increase, surging by over 1,100% from 2014 to 2023. This rise could indicate aggressive expansion or increased operational costs as the company scales.
Understanding these trends provides valuable insights into how different companies manage their operational costs, impacting their financial health and competitive positioning.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Viridian Therapeutics, Inc.
Pfizer Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Pfizer Inc. vs Biogen Inc. Trends and Insights
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.
Comparing SG&A Expenses: Pfizer Inc. vs Cytokinetics, Incorporated Trends and Insights
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.